-
公开(公告)号:US20110104186A1
公开(公告)日:2011-05-05
申请号:US11630550
申请日:2005-06-24
申请人: Nicholas Valiante , Feng Xu , Johanna Jansen , Susan Kaufman
发明人: Nicholas Valiante , Feng Xu , Johanna Jansen , Susan Kaufman
IPC分类号: A61K39/00 , C40B30/04 , A61K31/4439 , A61K31/496 , A61K31/56 , A61P31/14 , A61P35/00 , A61P37/08 , A61P11/06
CPC分类号: A61K31/7076 , A61K31/404 , A61K31/4184 , A61K31/437 , A61K31/4439 , A61K31/47 , A61K31/4706 , A61K31/4725 , A61K31/497 , A61K31/517 , A61K31/5377 , A61K31/7028 , A61K31/7056 , A61K31/706 , A61K31/7064 , A61K45/06 , Y02A50/388 , Y02A50/407 , Y02A50/466 , Y02A50/484 , Y02A50/59
摘要: The invention provides immunostimulatory compositions comprising a small molecule immuno-potentiator (SMIP) compound and methods of administration thereof. Also provided are methods of administering a SMIP compound in an effective amount to enhance the immune response of a subject to an antigen. Further provided are novel compositions and methods of administering SMIP compounds alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma. In a further aspect, the invention relates generally to methods of screening for small molecule immuno-modulatory compositions.
摘要翻译: 本发明提供包含小分子免疫增强剂(SMIP)化合物的免疫刺激组合物及其施用方法。 还提供了有效量施用SMIP化合物以增强受试者对抗原的免疫应答的方法。 还提供了单独或与另一种药物组合施用SMIP化合物以治疗癌症,感染性疾病和/或过敏/哮喘的新型组合物和方法。 在另一方面,本发明一般涉及筛选小分子免疫调节组合物的方法。
-
公开(公告)号:US20050203101A1
公开(公告)日:2005-09-15
申请号:US10839793
申请日:2004-05-05
申请人: Paul Barsanti , Dirksen Bussiere , Stephen Harrison , Carla Heise , Johanna Jansen , Elisa Jazan , Timothy Machajewski , Christopher McBride , William McCrea , Simon Ng , Zhi-Jie Ni , Sabina Pecchi , Keith Pfister , Savithri Ramurthy , Paul Renhowe , Cynthia Shafer , Joel Silver , Allan Wagman , Marion Wiesmann , Kelly Wayman
发明人: Paul Barsanti , Dirksen Bussiere , Stephen Harrison , Carla Heise , Johanna Jansen , Elisa Jazan , Timothy Machajewski , Christopher McBride , William McCrea , Simon Ng , Zhi-Jie Ni , Sabina Pecchi , Keith Pfister , Savithri Ramurthy , Paul Renhowe , Cynthia Shafer , Joel Silver , Allan Wagman , Marion Wiesmann , Kelly Wayman
IPC分类号: A61K31/4375 , A61K31/4709 , A61K31/496 , A61K31/52 , A61P35/00 , C07D401/04 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D453/02 , C07D453/06 , C07D471/04 , C07D43/14
CPC分类号: C07D401/04 , A61K31/4375 , A61K31/4709 , A61K31/496 , A61K31/52 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D453/02 , C07D453/06 , C07D471/04
摘要: Methods of treating cancer include contacting a cancer cell with 4-amino-5-fluoro-3-(5-piperazin-1-yl-1H-benzimidazol-2-yl)quinolin-2(1H)-one, 4-amino-5-fluoro-3-[5-(4-methyl-4-oxidopiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one, tautomers thereof, pharmaceutically acceptable salts thereof, pharmaceutically acceptable salts of the tautomers thereof, or a mixture thereof.
摘要翻译: 治疗癌症的方法包括使癌细胞与4-氨基-5-氟-3-(5-哌嗪-1-基-1H-苯并咪唑-2-基)喹啉-2(1H) - 酮,4-氨基-5- 5-氟-3- [5-(4-甲基-4-氧代哌嗪-1-基)-1H-苯并咪唑-2-基]喹啉-2(1H) - 酮,其互变异构体,其药学上可接受的盐,药学上可接受的 其互变异构体的盐或其混合物。
-
3.
公开(公告)号:US20080004433A1
公开(公告)日:2008-01-03
申请号:US11879719
申请日:2007-07-18
申请人: Dirksen Bussiere , Min He , Vincent Le , Johanna Jansen , S. Chin , Eric Martin
发明人: Dirksen Bussiere , Min He , Vincent Le , Johanna Jansen , S. Chin , Eric Martin
CPC分类号: C12N9/1205 , A61K38/00 , C07K2299/00
摘要: The invention provides the three-dimensional structure of a construct of glycogen synthase kinase 3 (GSK3); crystals of a construct of glycogen synthase kinase 3-β (GSK3-β) containing the protein's catalytic kinase domain; a method for crystallizing the protein construct to provide a GSK3 crystal sufficient for structure determination; and a method for using the GSK3 construct's three-dimensional structure for the identification of possible therapeutic compounds in the treatment of various disease conditions mediated by GSK3 activity.
摘要翻译: 本发明提供了糖原合酶激酶3(GSK3)构建体的三维结构; 含有蛋白质催化激酶结构域的糖原合成酶激酶3-β(GSK3-β)构建体的晶体; 使蛋白质构建体结晶以提供足以进行结构测定的GSK3晶体的方法; 以及使用GSK3构建体的三维结构来鉴定可能的治疗化合物以治疗由GSK3活性介导的各种疾病状况的方法。
-
公开(公告)号:US20060079564A1
公开(公告)日:2006-04-13
申请号:US11261995
申请日:2005-10-27
IPC分类号: A61K31/4184 , C07D403/04
CPC分类号: C07D403/04
摘要: Organic compounds having the structure I are provided where the variables have the values described herein. A method of inhibiting c-ABL in a patient includes administering an effective amount of a compound of structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, or a pharmaceutically acceptable salt of the tautomer to the patient.
摘要翻译: 提供具有结构I的有机化合物,其中变量具有本文所述的值。 抑制患者中c-ABL的方法包括向患者施用有效量的结构I化合物,化合物的互变异构体,化合物的药学上可接受的盐或互变异构体的药学上可接受的盐。
-
-
-